FIGO 2009 IB1期宫颈癌患者不辅以放疗的根治性子宫切除术:伴或不伴Sedlis阳性标准
符合Sedlis中危标准(除外>4 cm)者均未接受辅助放疗/放化疗,复发率10%。LVSI显著影响无进展生存和疾病特异性生存,而Sedlis风险因素组合未影响OS、DSS或PFS。
要点
- 符合Sedlis中危标准者未接受辅助放疗,复发率仍低至10%。
- LVSI是唯一显著影响PFS(HR 3.950)和DSS(HR 4.637)的风险因素。
- Sedlis风险因素组合未显著影响OS、DSS或PFS。
核心结论
- FIGO 2009 IB1期宫颈癌患者中,符合Sedlis中危标准但未接受辅助放疗/放化疗者复发率低(10%)。
- LVSI是唯一显著影响PFS和DSS的风险因素,而Sedlis风险因素组合未预测更差结局。
主要发现
- LVSI显著影响PFS(HR 3.950,p=0.0163)和DSS(HR 4.637,p=0.0497)。
- Sedlis风险因素组合(LVSI、肿瘤大小、DSI)未显著影响OS、DSS或PFS。
- 21例术后接受辅助治疗(RT 7例,CCRT 14例),因淋巴结阳性、切缘阳性或曾行简单子宫切除术。
关键数值与推荐
- Sedlis中危标准:LVSI、深间质浸润(>1/3)和肿瘤大小>4 cm中至少两项。
- 本研究排除肿瘤>4 cm者,符合Sedlis中危标准者均未接受辅助RT/CCRT。
临床怎么用
- 对于FIGO 2009 IB1期(≤4 cm)且符合Sedlis中危标准者,可不常规推荐辅助放疗,但需个体化评估。
- LVSI阳性者应加强随访,因其显著增加复发和疾病死亡风险。
局限性
- 未报告Sedlis中危标准亚组的具体复发数据及统计学比较。
- 辅助治疗方案异质(RT或CCRT),且部分因其他指征接受辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lymphovascular space invasion (LVSI), deep (>1/3) stromal invasion (DSI) and large tumor size (>4 cm) have been identified as predictors for intermediate risk for recurrence according to Sedlis (at least two of the prior risk factors) in FIGO stage I cervical cancer. Adjuvant radiotherapy (RT) has been advocated in these patients(1,2), but remains controversial. METHOD: All consecutive patients (1997-2017) with cervical cancer FIGO (2009) stage IB1 (≤4 cm) were included. Primary aim was to analyze the recurrence rate. Secondary aim was to identify the risk factors for disease recurrence and survival. RESULTS: One-hundred-and-eighty-two patients were included in this retrospective study. Median follow-up was 13 years (range 8-17). Postoperatively, 21 patients received adjuvant therapy due to presence of positive lymph nodes, positive section margins or if a simple hysterectomy was performed (RT: n = 7, concomitant chemo radiotherapy (CCRT): n = 14). None of the patients with a combination of intermediate risk factors according to Sedlis (excluding patients >4 cm) underwent adjuvant RT/CCRT. Disease recurrence was observed in 19 patients (10%). Eleven patients died of disease. LVSI influenced progression-free survival (PFS) (HR 3.950, p = 0.0163) and disease-specific survival (DSS) (HR 4.637, p = 0.0497) significantly. However, the combination of LVSI, tumor size and DSI according to Sedlis did not influence overall survival (OS), DSS or PFS. CONCLUSION: Recurrence rate was low (10%), despite the fact that patients with intermediate risk factors according to Sedlis did not receive postoperative RT/CCRT. LVSI was the sole risk factor influencing PFS and DSS. Combinations of risk factors according to Sedlis did not predict worse outcome.
引用
- Haesen J, Salihi R, Van Gorp T, et al. Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. Gynecol Oncol. 2021. PMID: 34253389. doi:10.1016/j.ygyno.2021.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。